Drug Name】Disodium Cantharidinate Tablets

[Ingredients] Chemical name: Sodium Cantharidinate. Molecular formula: C10H12O5Na2, molecular weight: 258.1

Properties】This product is white tablets.

Indications】Anti-tumor drug. Used for primary liver cancer and other tumors and leukocyte hypoplasia. Also used for hepatitis, cirrhosis and hepatitis B virus carriers.

Specifications】0.5mg

Dosage】Orally. 2 times a day, 0.5~1mg each time.

Adverse effects]: Not yet clear.

Contraindication] Cardiac and renal insufficiency, bleeding tendency is prohibited.

Precautions

1、Use with caution in renal insufficiency.

2, urinary and digestive system irritation reaction, can reduce the dosage or suspend the use of drugs.

Pregnant and lactating women】Pregnant and lactating women are prohibited.

Children with bladder, liver, kidney, heart and lung tissue development should be avoided.

Geriatric Use] Not known.

Drug interactions] Not known.

Overdose] Not known.

1. Pharmacology.

a. Sodium zebranoate can inhibit the synthesis of protein and nucleic acid in tumor cells, and then affect the biosynthesis of RNA and DNA(1), and ultimately inhibit the generation and division of cancer cells.

b. Sodium zebranoate can reduce the activity of CAMP phosphodiesterase in tumor cells and increase the activity of catalase. It both improves cellular energy metabolism and reduces the level of cancer-toxic hormones.

c.Experiments show that sodium zebranoate can directly enter the nucleus and nucleolus of mouse ascites hepatocellular carcinoma cells. It inhibits the DNA and RNA content and the infiltration of precursors in cancer cells, proving that it acts on the nucleic acid metabolism of cancer cells, and then causes changes in the morphology and function of cancer cells and kills cancer cells. Sodium Zanthate can also stimulate bone marrow hematopoietic system and elevate white blood cells.

2、Toxicology:Tests of acute toxicity, hemolysis and irritation of this product, the results are as follows.

a.Mouse oral LD50 is 4.16mg/kg.

b. Mouse intraperitoneal injection LD50 is 4.39mg/kg

c. No in vitro hemolytic reaction.

d. No irritation to the gastrointestinal tract of rabbits and mice.

Pharmacokinetics] The product is absorbed quickly and completely from the digestive tract, labeled with H, the concentration in blood peaks in 12 hours, and only trace radioactivity is measurable after 24 hours; after oral administration, the radioactivity is high in the bladder and bile, followed by tissues of the kidney, liver, heart, lungs, and stomach; at the same time, most of the drug is excreted from the urine.

Storage】Store under light.

Package】Aluminum composite plate, 3 tablets/plate/box.

【Effective period】Temporary 24 months

Execution Standard]: National Drug Standard (Trial) WS-10001-(HD-1290)-2002

Approval Number]: National Pharmaceutical Standards (Trial) WS-10001-(HD-1290)-2002